Moulinath Banerjee
Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi